BACKGROUND: Natural killer T (NKT) cells are a heterogeneous population of innate T cells that have attracted interest because of their potential to regulate immune responses to a variety of pathogens. The most widely studied NKT cell subset is the invariant (i)NKT cells that recognize glycolipids in the context of the CD1d molecule. The multifaceted methods of activation iNKT cells possess and their ability to produce regulatory cytokines has made them a primary target for studies. OBJECTIVE/ METHODS: To give insights into the roles of iNKT cells during infectious diseases, particularly viral infections. We also highlight mechanisms leading to iNKT cell activation in response to pathogens. CONCLUSIONS: iNKT cell's versatility allows them to detect and respond to several viruses. Therapeutic approaches to specifically target iNKT cells will require additional research. Notably, the roles of non-invariant NKT cells in response to pathogens warrant further investigation.
BACKGROUND: Natural killer T (NKT) cells are a heterogeneous population of innate T cells that have attracted interest because of their potential to regulate immune responses to a variety of pathogens. The most widely studied NKT cell subset is the invariant (i)NKT cells that recognize glycolipids in the context of the CD1d molecule. The multifaceted methods of activation iNKT cells possess and their ability to produce regulatory cytokines has made them a primary target for studies. OBJECTIVE/ METHODS: To give insights into the roles of iNKT cells during infectious diseases, particularly viral infections. We also highlight mechanisms leading to iNKT cell activation in response to pathogens. CONCLUSIONS: iNKT cell's versatility allows them to detect and respond to several viruses. Therapeutic approaches to specifically target iNKT cells will require additional research. Notably, the roles of non-invariant NKT cells in response to pathogens warrant further investigation.
Authors: Hans J J van der Vliet; B Mary E von Blomberg; Mette D Hazenberg; Nobusuke Nishi; Sigrid A Otto; Birgit H van Benthem; Maria Prins; Frans A Claessen; Alfons J M van den Eertwegh; Giuseppe Giaccone; Frank Miedema; Rik J Scheper; Herbert M Pinedo Journal: J Immunol Date: 2002-02-01 Impact factor: 5.422
Authors: T Kawano; J Cui; Y Koezuka; I Toura; Y Kaneko; K Motoki; H Ueno; R Nakagawa; H Sato; E Kondo; H Koseki; M Taniguchi Journal: Science Date: 1997-11-28 Impact factor: 47.728
Authors: A W Jahng; I Maricic; B Pedersen; N Burdin; O Naidenko; M Kronenberg; Y Koezuka; V Kumar Journal: J Exp Med Date: 2001-12-17 Impact factor: 14.307
Authors: Joseph L Amprey; Jin S Im; Salvatore J Turco; Henry W Murray; Petr A Illarionov; Gurdyal S Besra; Steven A Porcelli; Gerald F Späth Journal: J Exp Med Date: 2004-10-04 Impact factor: 14.307
Authors: Mark A Exley; Lydia Lynch; Bindu Varghese; Michael Nowak; Nadia Alatrakchi; Steven P Balk Journal: Clin Immunol Date: 2011-05-13 Impact factor: 3.969
Authors: Hadi Maazi; Abinav K Singh; Anneliese O Speak; Vincent Lombardi; Jonathan Lam; Bryant Khoo; Kyung Soo Inn; Arlene H Sharpe; Jae U Jung; Omid Akbari Journal: PLoS One Date: 2013-03-15 Impact factor: 3.240